Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer-Reference-Cited by-同舟云学术

Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer

Published:2017-06-21 Issue:7 Volume:6 Page:1552-1562
ISSN:2045-7634
Container-title:Cancer Medicine
language:en
Short-container-title:Cancer Med

Author:

Shrestha Bikram¹²,Sun Yifei³⁴,Faisal Farzana¹²,Kim Victoria⁵²,Soares Kevin⁵²,Blair Alex⁵²,Herman Joseph M.¹⁶²⁷,Narang Amol⁶²,Dholakia Avani S.⁶²,Rosati Lauren⁶²,Hacker-Prietz Amy⁶²,Chen Linda⁶²,Laheru Daniel A.¹²,De Jesus-Acosta Ana¹²,Le Dung T.¹²,Donehower Ross¹²,Azad Nilofar¹²,Diaz Luis A.¹²,Murphy Adrian¹²,Lee Valerie¹²,Fishman Elliot K.¹⁸²,Hruban Ralph H.¹⁹²,Liang Tingbo¹⁰^ORCID,Cameron John L.¹⁵²,Makary Martin¹⁵²,Weiss Matthew J.¹⁵²,Ahuja Nita¹⁵²,He Jin¹⁵²,Wolfgang Christopher L.¹⁵²,Huang Chiung-Yu³⁴,Zheng Lei¹⁵²^ORCID

Affiliation:

1. Department of Oncology; The Johns Hopkins University School of Medicine; Baltimore Maryland

2. Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore Maryland

3. Division of Biostatistics and Bioinformatics; Sidney Kimmel Comprehensive Cancer Center; The Johns Hopkins University School of Medicine; Baltimore Maryland

4. Department of Biostatistics; Johns Hopkins Bloomberg School of Public Health; Baltimore Maryland

5. Department of Surgery; The Johns Hopkins University School of Medicine; Baltimore Maryland

6. Department of Radiation Oncology; The Johns Hopkins University School of Medicine; Baltimore Maryland

7. Department of Radiation Oncology; M.D. Anderson Cancer Center; Houston Texas

8. Department of Radiology; The Johns Hopkins University School of Medicine; Baltimore Maryland

9. The Sol Goldman Pancreatic Cancer Research Center; Department of Pathology; The Johns Hopkins University School of Medicine; Baltimore Maryland

10. The Second Affiliated Hospital of Zhejiang University; Hangzhou China

Funder

National Institutes of Health

Viragh Foundation and the Skip Viragh Pancreatic Cancer Center at Johns Hopkins

Lefkofsky Family Foundation

NCI SPORE in Gastrointestinal Cancers

Lustgarten Foundation

Publisher

Wiley

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cam4.1104/fullpdf

Reference22 articles.

1. Multidisciplinary management of pancreatic cancer;Kumar;Surg. Oncol. Clin. N. Am.,2013

2. Recent progress in pancreatic cancer;Wolfgang;CA Cancer J. Clin.,2013

3. Pretreatment assessment of resectable and borderline resectable pancreatic cancer: expert consensus statement;Callery;Ann. Surg. Oncol.,2009

4. Borderline resectable/locally advanced pancreatic adenocarcinoma: improvements needed in population-based registries;Miura;Ann. Surg. Oncol.,2013

5. Potential contribution of preoperative neoadjuvant concurrent chemoradiation therapy on margin-negative resection in borderline resectable pancreatic cancer;Kang;J. Gastrointest. Surg.,2012

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Can Concurrent Chemoradiotherapy Add Meaningful Benefit in Addition to Induction Chemotherapy in the Management of Borderline Resectable and Locally Advanced Pancreatic Cancer?;Pancreas;2023-01

2. Exercise intervention during chemotherapy for pancreatic cancer: Changes in body composition and function;JCSM Rapid Communications;2023-01

3. Use of endoscopic ultrasound for pancreatic cancer from 2000 to 2016;Endoscopy International Open;2022-01

4. Role of radio‑ablative technique for optimizing the survival of patients with locally advanced pancreatic adenocarcinoma (Review);Experimental and Therapeutic Medicine;2021-06-08

5. Pancreatic Cancer: “Whether to Cross the Border”?;Indian Journal of Surgical Oncology;2021-05-08